Pregled bibliografske jedinice broj: 1271190
Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes
Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes // Frontiers in Oncology, 13 (2023), 1114701, 18 doi:10.3389/fonc.2023.1114701 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1271190 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Estimating complete cancer prevalence in Europe:
validity of alternative vs standard completeness
indexes
Autori
Demuru, Elena ; Rossi, Silvia ; Ventura, Leonardo ; Dal Maso, Luigino ; Guzzinati, Stefano ; Katalinic, Alexander ; Lamy, Sebastien ; Jooste, Valerie ; Di Benedetto, Corrado ; De Angelis, Roberta ; the EUROCARE-6, Working Group ; Sekerija, Mario
Kolaboracija
EUROCARE-6 Working Group
Izvornik
Frontiers in Oncology (2234-943X) 13
(2023);
1114701, 18
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
EUROCARE ; Europe ; SEER program ; cancer prevalence ; cancer registries ; cancer survivors ; cancer survivorship
Sažetak
Introduction: Comparable indicators on complete cancer prevalence are increasingly needed in Europe to support survivorship care planning. Direct measures can be biased by limited registration time and estimates are needed to recover long term survivors. The completeness index method, based on incidence and survival modelling, is the standard most validated approach. Methods: Within this framework, we consider two alternative approaches that do not require any direct modelling activity: i) empirical indices derived from long established European registries ; ii) pre-calculated indices derived from US-SEER cancer registries. Relying on the EUROCARE-6 study dataset we compare standard vs alternative complete prevalence estimates using data from 62 registries in 27 countries by sex, cancer type and registration time. Results: For tumours mostly diagnosed in the elderly the empirical estimates differ little from standard estimates (on average less than 5% after 10-15 years of registration), especially for low prognosis cancers. For early-onset cancers (bone, brain, cervix uteri, testis, Hodgkin disease, soft tissues) the empirical method may produce substantial underestimations of complete prevalence (up to 20%) even when based on 35-year observations. SEER estimates are comparable to the standard ones for most cancers, including many early-onset tumours, even when derived from short time series (10-15 years). Longer observations are however needed when cancer-specific incidence and prognosis differ remarkably between US and European populations (endometrium, thyroid or stomach). Discussion: These results may facilitate the dissemination of complete prevalence estimates across Europe and help bridge the current information gaps.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita
POVEZANOST RADA
Ustanove:
Hrvatski zavod za javno zdravstvo,
Medicinski fakultet, Zagreb
Profili:
Mario Šekerija
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus